ABSTRACT The RIG-I/MAVS signaling stimulates anti-tumor immunity by triggering the production of inflammatory cytokines. Activation of MAVS induced by viral RNA and RIG-I binding is critical

in this pathway. However, the molecular mechanism underlying the regulation of MAVS activity and its function in anti-tumor immunity is not fully understood. Here, we report that the

ubiquitin-specific protease 35 (USP35) negatively regulates the MAVS signaling. Mechanistically, USP35 interacts with MAVS and removes its K63-linked polyubiquitin chains, thereby inhibiting

viral-induced MAVS-TBK1-IRF3 activation and downstream inflammatory gene expression. Importantly, depletion of USP35 significantly enhances the anti-tumor immunity and synergizes with

Article Open access 03 February 2025 ERK AND USP5 GOVERN PD-1 HOMEOSTASIS VIA DEUBIQUITINATION TO MODULATE TUMOR IMMUNOTHERAPY Article Open access 19 May 2023 USP2 PROMOTES TUMOR IMMUNE

EVASION VIA DEUBIQUITINATION AND STABILIZATION OF PD-L1 Article 05 September 2023 INTRODUCTION Melanoma is one of the most common malignant tumors worldwide, and its morbidity and mortality

are increasing annually [1]. In total, 324,635 new cases and 57,043 deaths from melanoma were registered in the GLOBOCAN 2020 database [2]. Although immunotherapy, including anti-PD-1/PD-L1

and anti-CTLA-4 antibodies, as well as oncolytic virotherapy, have emerged as the treatment for advanced or metastatic melanoma [3], a significant proportion of patients either did not

respond to these therapies or developed secondary resistance [4]. Therefore, there is an urgent need to develop new therapeutic strategies for treatment efficacy. The RIG-I-MAVS signaling

pathway plays a crucial role in antiviral immunity and the anti-tumor immune response [5,6,7]. Sensing viral RNA or RNA analogs by RLRs (RIG-I-like receptors) results in activating and

interacting with the adapter protein mitochondrial antiviral signaling protein (MAVS) to induce MAVS oligomerization [8]. Subsequently, the oligomerized MAVS activates TRAFs, which leads to

the activation of interferon kinases such as TBK1 and IKKe. Then, the activated kinases phosphorylate IRF3 and IRF7, facilitating IRF3 translocation into the nucleus to stimulate the

transcription of type I interferon and cytokine genes [9]. Thus, activation of MAVS is a critical step for transducing RLRs-mediated signaling. Recent studies have revealed that MAVS

activity is regulated by ubiquitination [10, 11]. The E3 ubiquitin ligase TRIM31-mediated ubiquitination of MAVS is required for RIG-I-induced MAVS oligomerization and activation [12].

K27-linked ubiquitination by TRIM21 also enhances MAVS activity [13]. However, the mechanisms of deubiquitination of MAVS and its role in anti-tumor immunity are not fully understood.

Deubiquitinating enzymes (DUBs) are known to be involved in tumorigenesis and are considered potential therapeutic targets [14]. The ubiquitin-specific protease 35 (USP35) is a member of the

USPs family implicated in mitophagy, cell survival, ER stress, and mitotic progression [15]. Depletion of USP35 promotes ferroptosis and suppresses lung cancer cell growth and tumor

progression [16]. Of note, USP35 negatively regulates STING activity in the DNA-sensing pathway [17]. However, its role in RNA sensing and malignant melanoma remains largely unexplored.

Here, we explore the function of USP35 in MAVS signaling and find that USP35 acts as a negative regulator of MAVS-mediated type I interferon production. USP35 directly binds to MAVS and

removes the K63-linked polyubiquitin chain of MAVS, a process dependent on the enzyme activity of USP35. Knockdown of USP35 combined with oncolytic virus significantly promotes the immune

infiltration of CD8+ T cells and the release of IFNβ and inflammatory factors CXCL10 and CCL5, ultimately inhibiting the growth of malignant melanoma, Overall, our findings identify USP35 as

a previously undescribed regulator of MAVS pathway, and targeting USP35 provides a strategy for immunotherapy of malignant melanoma. MATERIALS AND METHODS VSV VIRUS VSV-GFP was kindly

provided by Professor Chengjiang Gao at Shandong University. The virus was amplified from VERO cells and stored at −80 °C. Recombinant Human Adenovirus Type 5 injection (Oncorine, H101) was

sponsored by Shanghai Sanwei Biotechnology Co., Ltd. PLASMIDS pcDNA3.1-Flag-USP35, pcDNA3.1-Flag-USP35(C450A), pcDNA3.1-Myc-USP35, pcDNA3.1-Flag-MAVS, pcDNA3.1-Flag-TBK1,

pcDNA3.1-Flag-RIG-I, pcDNA3.1-HA-Ub WT, pcDNA3.1-HA-Ub-K6, K11, K27, K29, K33, K48, K63, and different truncations of USP35 and MAVS were generated by PCR and sub-cloned into the pcDNA3.1

vector. 4T-2-USP35 was constructed by PCR and sub-cloned into the 4T-2 vector. All plasmids were confirmed by DNA sequencing. REAGENTS AND ANTIBODIES The 3pRNA was purchased from Invitrogen,

M2 beads (Sigma, F24265X), and ProteinA/G Plus agarose magnetic beads (Santa Cruz, P2138), and GST beads (Yisheng Biotechnology, 20507ES60) were acquired commercially. The antibodies and

reagents used in this study were purchased from commercial sources: anti-Flag (Diagbio, #db7002), anti-Myc (Diagbio, #db457), anti-HA (Diagbio, #db2603), anti-USP35 (LSBio, LSC353839),

anti-MAVS (Abcam, ab189109), anti-TBK1 (38066), anti-IRF 3 (CS, 4302), Rabbit anti-phospho TBK1 (Ser172) (CST, 5483), anti-phospho IRF3 (CST, 29047), anti-IgG (Abcam, ab109489), anti-GAPDH

(Proteintech, 104941AP), Dual-Glo luciferase assay kit (Promega), and Glutathione Sepharose 4B (GE Healthcare). CONSTRUCTION OF CELL LINES STABLY INFECTED WITH SHRNA AND SGRNA shRNA empty

vector and a control luciferase shRNA in pLKO.1 lentiviral vector were obtained from Professor Jian Luo (East China Normal University, Shanghai, China). The shRNA targeting hUSP35 and mUSP35

were constructed by plasmid pLKO.1 and transfected by PEI or transferred by lentivirus into cells. The shRNA lentiviruses were packaged by cotransfection of the control or shRNA vector

together with psPAX2 and pMD2.G into HEK293. Eight hours later, the medium was changed to fresh medium (10% FBS, 1% streptomycin–penicillin). Forty hours later, the supernatants were

harvested and filtered with a 0.45 μm filter to infect B16F10, HeLa, Yummer1.7, and ID8 cells in the presence of polybrene (8 μg/mL). At twenty-four hours post-infection, cells were selected

with puromycin (2–10 μg/mL) for 7 days before experiments. We acquired the sgRNA sequence from http://cistrome.org/crispr-focus. After annealing of the foward and reverse primers, the

annealed sgRNA fragment was inserted into the pLentiguide-Puro vector by molecular cloning. All plasmids were confirmed by sequencing. CELL CULTURE AND TRANSFECTION HEK293T, HeLa, B1610,

ID8, A375, and VERO cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences, and YUMMER1.7 cell was purchased from ATCC. They were authenticated by STR profiling

and tested for mycoplasma contamination. All cells were cultured in a 37 °C incubator containing 5% CO2, medium: DMEM with 10% FBS. The density of HEK293T in the plate was up to 60~70%, and

transfection was performed using PEI reagent. 200 μl DMEM medium was added to a 1.5 ml sterile EP tube, and then the corresponding volume of PEI was added according to the ratio of the

plasmid: PEI = 1 μg:3 μl. After 15 min, the mixture was added to a petri dish with DMEM and placed back into the incubator for further incubation. REAL-TIME RT-PCR Total RNA was extracted

from cells using TRIzol reagent (Vazyme Biotech Co., Ltd) according to the manufacturer’s directions and treated with RNase-free DNase. Total RNAs (1000 ng) were used to perform the reverse

transcription with HiScript II One-Step RT-PCR Kit (P611-01, Vazyme). Total RNA was extracted and assayed by real-time PCR as described with the SYBR green master mix. Primers were shown in

Table S1. Data were analyzed with bio-rad software. Data were normalized by β-actin expression level in each sample. 2−ΔΔCt method was used to calculate relative expression changes.

CO-IMMUNOPRECIPITATION (CO-IP) AND IMMUNOBLOT ANALYSIS Transfected cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 1 mM EDTA, 0.5% Nonidet P-40, PMSF,

Na3VO4, and NaF) and cleared by centrifugation. Cleared cell lysates were incubated with 8 μl of Flag or HA beads for 3 h at 4 °C. After incubation at 4 °C, beads were washed three times

with lysis buffer. The beads were then supplemented with 50 μl of protein loading buffer (2×), mixed well, and cooked at 100 °C for 5 min. Thendo the Western Blot experiments. To detect

endogenous protein interactions, cells were lysed in ice-cold lysis buffer. Cleared cell lysates were incubated with the indicated antibody and 16 µl of protein A/G beads for 3 h at 4 °C.

After extensive washing, beads were boiled at 100 °C for 5 min. Proteins were resolved by SDS-PAGE and transferred onto nitrocellulose (NC) membranes (EMD Millipore), followed by

immunoblotting using indicated antibodies. Immunoblots were analyzed using the Odyssey system (LI-COR Biosciences). For western blot analysis, equal amounts of cell lysates and

immunoprecipitants were resolved on a 10–12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to an NC membrane (Cat#10639710; GE Whatman). After incubation

with primary and secondary antibodies, the membranes were visualized by ECL chemiluminescence (Cat#32106; Thermo Fisher Scientific, Waltham, MA, USA). LUCIFERASE REPORTER GENE ASSAY The

HEK293T were seeded one day earlier in 24-well plates with 2 wells for each group and transfection of each group of plasmid by PEI on the following day according to the manufacturer’s

instructions. 20 ng Renila, 100 ng of IFN luciferase, 1 µg of expression plasmids including MAVS, TBK1, RIG-I, and USP35 was added to each well. Luciferase activity was measured at 24 h

after transfection via the Dual-Glo Luciferase Assay System. Relative IFNβ expression was calculated as firefly luminescence relative to Renilla luminescence. UBIQUITINATION ASSAY In vivo

deubiquitination assays were performed as described previously [18]. In brief, Flag-MAVS constructs were transiently transfected into 293T with or without HA-ubiquitin and USP35 WT/CA. Cells

were lysed with the lysis buffer (100 μl), and the supernatants were denatured at 95 °C for 5 min in the presence of 2% SDS by lysates. The denatured lysates were diluted with lysis buffer

until the concentration of SDS reduced below 0.2%, followed by immunoprecipitation (denature-IP) with the indicated antibodies. The immunoprecipitants were subject to immunoblot analysis

with anti-ubiquitin, Aspirate the residual washing buffer, and boil the resin with 2× SDS loading buffer. Load samples onto SDS-PAGE gel for immunoblotting analysis. For analysis of the

ubiquitination of endogenous MAVS in cells, Cells were treated with the indicated stimulation, then whole-cell extracts (denature-)were immunoprecipitated with anti-MAVS and analyzed by

immunoblot with indicated antibodies. PROTEIN PURIFICATION AND GST PULL-DOWN ASSAY The plasmids encoding GST-Vector and GST-USP35 were transformed into BL21 DE3 competent cells, which were

induced with IPTG (1 mM) at 18 °C for 8 h. The cells were lysed in lysis buffer (20 mM Tris–HCl, 150 mM NaCl, 10% glycerol, and 0.5% Triton X-100). For GST pull-down analysis, purified

recombinant GST-fusion proteins were incubated with preequilibrated glutathione-Sepharose beads for 2 h followed by extensive washing. The preloaded GST resins were incubated with FLAG-MAVS

lysate protein from 293 T, respectively, for 3 h at 4 °C. Precipitates were extensively washed and subjected to SDS-PAGE, followed by immunoblot analysis. TUMOR GROWTH AND ONCOLYTIC

INTRATUMORAL INJECTION We purchased male C57BL/6 mice aged 5–6 weeks from Shanghai Bikai Experimental Animal Company. Animals were randomly assigned to the various experimental groups. Eight

mice were used per group. B16F10 were collected, and the number of inoculated cells was 5 × 106 per mouse. When the tumor grew to about 6 mm, the above groups were randomly divided, and the

middle of the tumor was punctured with a 1 ml sterile syringe, and H101 or PBS was injected slowly. D12, d15, d18, d21, d23, H101: 1.5 × 109 vp (diluted with PBS to 50 µl) were injected

intratumorally. Tumor volume was measured at 2-day intervals. Tumor volume (mm3) = long diameter and short diameter2/2, all results are expressed as mean ± SEM and analyzed by two-sample

t-test. *_P_ < 0.05, **_P_ < 0.01, ***_P_ < 0.001, ns, not statistically significant. When the diameter of the tumor in the control group of mice reached 15 mm, the mice were

killed, and the tumors were removed. FLOW CYTOMETRY After tumor tissue was ground and digested by 1 mg/ml collagenase IV (Yeasen, 40510ES60) and 0.2 mg/ml DNase I (Sigma,9003-98-9) for 1 h

at 37 °C, suspension cells were stained with fluorescence-labeled antibodies against Percerp-CD45, FITC-CD3, PE-CD4, APC-CD8, Percerp-CD45, FITC-CD206, PE-F4/80and CD11b. Flow cytometry was

performed using BD LSRFortessa at the core facility of Tongji University, and data were analyzed with FlowJo software. THE VSV VIRUS AND THE 3PRNA ACTIVATE THE RNA-SENSING SIGNALING PATHWAY

VSV was propagated and tittered by plaque assays on VERO cells. Transfection of 3p-RNA was performed according to the appropriate instructions. Samples were collected at different time

points post-infection and subjected to RT-qPCR or WB assay. SEMI-DENATURING DETERGENT AGAROSE GEL ELECTROPHORESIS (SDD-AGE) Semi-denaturing detergent agarose gel electrophoresis (SDD–AGE)

was performed according to a published protocol with minor modifications [12]. Western-blot semi-dry transfer protocol was used to test the oligomerization of MAVS. ELISA The concentration

of IFNβ and CXCL10 was measured by Human IFNβ and CXCL10 ELISA kit (BioResearch company). CONFOCAL MICROSCOPY 293T were transfected with GFP-USP35 and Flag-MAVS expressing plasmids. After 24

 h, cells were stimulated for the indicated time with VSV, and then cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Next, the cells were rinsed once with PBS and

fixed in 4% paraformaldehyde for 15 min at room temperature. The fixed cells were permeabilized using 0.1% Triton X-100 and rinsed twice with PBS. The coverslips were blocked with blocking

buffer for 1 h (0.3% BSA in PBS) and incubated in a primary antibody in blocking buffer overnight at 4 °C. Next, the coverslips were rinsed twice with blocking buffer and incubated in

secondary antibodies for 1 h at room temperature in the dark. The glass coverslips were mounted using Mowiol and were examined using an LSM 510 Meta confocal system (ZEISS) under a 100× oil

objective. STATISTICAL ANALYSIS All the data in this study were analyzed by GraphPad Prism 8 software and the data analysis was shown as Mean ± SEM. The T-test was used to assess pairwise

statistical significance, and the one-way ANOVA test was used to assess statistical differences between multiple groups. A two-way repeated measures analysis of variance (ANOVA) was carried

out to evaluate the effect of the time (before and after intervention) and the impact of time-group interaction. Where *_P_ < 0.05, **_P_ < 0.01, ***_P_ < 0.001, ns is no

statistical difference. Statistical analyses other than the online database were performed using R software (v4.0.2). Correlation tests were performed using personal correlation analysis.

RESULTS USP35 IS HIGHLY EXPRESSED IN MALIGNANT MELANOMA PATIENTS AND CORRELATED WITH TUMOR IMMUNE-RELATED CELL INFILTRATION To explore the expression level of USP35 in pan-cancer, we first

performed bioinformatics analysis using TCGA datasets and found that USP35 was significantly up-regulated in multiple tumor tissues, including melanoma and other types of cancer (Fig. 1A).

Further analysis of USP35 expression in the cBioPortal database showed that USP35 had the highest proportion of genomic alterations in melanoma among 26 types of tumors, gene amplification

being the most frequent alteration (Fig. 1B). Genetic alterations of USP35 were also observed in approximately 11% of cases of cutaneous melanoma in the SKCM dataset of TCGA (_n_ = 40/363),

including copy number amplification (_n_ = 14), multiplex alterations (_n_ = 14), and missense mutations (_n_ = 10) (Fig. 1C). The lollipop diagram displayed that most mutations occurred in

the ubiquitin carboxyl-terminal hydrolase (UCH) domain (Fig. 1D), potentially leading to truncation of USP35 and loss of its deubiquitination activity. Next, we investigated the expression

level of USP35 after anti-PD-1 or CTLA-4 treatment by analyzing the data from the GEO database. The mRNA expression level of USP35 was significantly increased after anti-PD-1 or anti-CTLA-4

treatment compared with IgG treatment (Fig. 1E), suggesting USP35 may play a role in tumor immunity. We also explored the relationship between the expression level of USP35 and the overall

survival (OS) of patients with melanoma using the GEPIA database. Kaplan–Meier survival curves indicated that patients with high USP35 expression levels had poorer OS (_P_ = 0.038, HR = 1.3)

(Fig. 1F). These findings suggest that USP35 is highly expressed in malignant melanoma tissues and is associated with poor prognosis in patients with melanoma. To assess whether USP35 is

associated with the tumor microenvironment in malignant melanoma, we conducted immune infiltration estimation by six algorithms, including xCell, QUANTISEQ, MCPcounter, EPIC, CIBERSORTABS,

and CIBERSORT. As shown in the bubble plot, USP35 expression was positively correlated with the immune infiltration of Treg cells, M2 macrophages, and neutrophils, and negatively correlated

with infiltration of B cells, CD8+ T cells, CD4+ T cells, M1-type macrophages, and dendritic cells (Supplementary Fig. 1A). Similar results were also observed using xCELL and CIBERSORT

algorithms (Supplementary 1B–G). These data suggest that the expression of USP35 was negatively correlated with the infiltration of immune cells in tumors. USP35 INHIBITS THE ACTIVATION OF

THE TYPE I INTERFERON SIGNALING PATHWAY BY MAVS Since the RIG-I-MAVS pathway plays a key role in promoting anti-tumor T-cell infiltration, we next investigated whether USP35 regulates this

signaling. Dual luciferase reporter assay displayed that ectopic expression of wild-type USP35, but not the catalytically inactive USP35-C450A mutant, inhibited MAVS-induced IFNβ luciferase

reporter (IFNβ-Luc) activity (Fig. 2A). Furthermore, USP35 was found to inhibit RIG-I, but not TBK1-activated IFNβ-Luc expression (Fig. 2B), suggesting that the regulation is at the layer of

RIG-I-MAVS. IFN activates the expression of interferon-stimulated genes (ISGs), which contain ISRE (interferon-stimulated response element) elements in the promoters [19]. we also found

that USP35 also inhibited RIG-I or MAVS-induced ISRE-Luc activity (Fig. 2B). Next, we explored whether USP35 regulates RIG-I/MAVS-mediated expression of the interferon and related

inflammatory factors. In mouse malignant melanoma cell lines B16F10 and Yummer1.7, knockdown of USP35 by shRNAs, which specifically targeted USP35 mRNA, significantly enhanced VSV

virus-induced expression of inflammation and antiviral-associated factors, including IFNβ, CXCL10, and ISG15 (Supplementary Fig. 2A, B; Fig. 2C, D). Similar results were also observed in

HeLa and ID8 cells (Fig. 2E, F, Supplementary Fig. 2C, D). Viral RNAs activate the innate immune receptor retinoic acid-inducible gene I (RIG-I)-like receptor (RLR). Short double-stranded

RNA (dsRNA) with both 5’-triphosphate part-5’-triphosphate RNA (3p-RNA) is a specific ligand for RIG-I [20]. Upon binding to 3p-RNA, RIG-I triggers downstream signaling through IFN

regulatory factor 3 (IRF3), mitogen-activated protein kinase (MAPK), and NF-κB pathways via MAVS. We used 3pRNA to activate RIGI/MAVS signaling and found that the mRNA expression level of

IFNβ, CXCL10, and ISG15 was significantly enhanced by USP35 depletion (Fig. 2G). Furthermore, ELISA experiments further confirmed that the protein levels of IFN-β and CXCL10 were increased

in USP35-knockdown cells (Supplementary Fig. 2H). Taken together, these findings suggest that USP35 is a negative regulator of RIG-I-MAVS signaling. USP35 INTERACTS WITH MAVS IN VIVO AND IN

VITRO To investigate the mechanism how USP35 inhibits the RIG-I-MAVS pathway, we examined the interaction between USP35 and MAVS. Co-immunoprecipitation (Co-IP) experiments in 293 T

co-transfected with Myc-USP35 and Flag-tagged RIG-I, MAVS, or TBK1 showed that USP35 strongly interacted with MAVS (Fig. 3A, B). Reciprocal Co-IP assay displayed that endogenous USP35 could

bind to endogenous MAVS (Fig. 3D, E). To validate whether USP35 directly interacts with MAVS, we performed a GST Pull-down assay using the purified USP35 protein and detected a direct

interaction between GST-USP35 and MAVS (Fig. 3F). To explore whether the binding of USP35 to MAVS is regulated by VSV virus stimulation, we infected cells with the VSV virus. The interaction

between USP35 and MAVS was enhanced in a time-dependent manner following VSV treatment (Fig. 3C). Immunofluorescence staining further confirmed the colocalization of USP35 with MAVS upon

RNA infection (Supplementary Fig. 2D). MAVS contains an N-terminal CARD-like domain and a C-terminal transmembrane domain TM [21]. To identify the domains involved in the binding of USP35 to

MAVS, we constructed a series of truncations of MAVS. Co-IP experiments showed that the transmembrane domains of MAVS interacted with USP35 (Fig. 3G). Additionally, we created a series of

truncated mutants of USP35 and found that MAVS could bind to the USP structural domain at the C-terminus of USP35 (Fig. 3H). Taken together, these results suggest that USP35 interacts with

MAVS both in vivo and in vitro, and this interaction is regulated by viral stimulation. USP35 MODIFIES MAVS THROUGH K63 CHAIN DEUBIQUITINATION Since USP35 is a key member of the

deubiquitination enzyme family, we explored whether USP35 regulates the ubiquitination of MAVS. The ubiquitination experiments showed that USP35-WT, but not catalytically inactive

USP35-C450A mutant could deubiquitinate MAVS (Fig. 4A). In contrast, both USP35-WT and USP35-CA had no significant effect on the ubiquitination of RIG-I or TBK1 (Fig. 4B, C), indicating that

USP35 specifically deubiquitinates MAVS. Moreover, the knockdown of USP35 promoted the ubiquitination of endogenous MAVS (Fig. 4E). To explore which type of polyubiquitin linkage on MAVS is

targeted by USP35, we co-transfected MAVS with WT-ubiquitin or different ubiquitin variants. Our data showed that USP35 could remove K6, K11, K27, K33, K29, K48, and K63-linked

polyubiquitin chains from MAVS (Supplementary Fig. 3A). Viral infection has been shown to lead to K63-type linked ubiquitination of MAVS at the mitochondrial outer membrane which

subsequently induces MAVS aggregation and activation [12]. We co-expressed MAVS-Flag, USP35-Myc, and HA-Ub or HA-Ub K63O (K63 only) in 293 T. The results showed that USP35 removed the

K63-type ubiquitination of MAVS (Fig. 4D). Semi-denaturing gel electrophoresis (SDD-AGE) was performed to examine MAVS multimerization. The results showed that USP35 knockdown increased the

level of MAVS multimerization induced by RNA infection (Supplementary Fig. 3B). Furthermore, the half-life of MAVS protein was also not significantly changed by USP35 knockdown or

overexpression. These results indicate that USP35 does not affect the stability of MAVS(Supplementary Fig. 3D, E). Together, these data suggest that USP35 is a deubiquitinase for MAVS. USP35

REGULATES THE MAVS-TBK1-IRF3 SIGNALING PATHWAY Next, we investigated whether USP35 regulates MAVS activity. RIG-I-MAVS signaling triggers phosphorylation and activation of TBK1/IRF3, which

stimulates IRF3-mediated transcription of interferon and pro-inflammatory cytokines [22]. To explore this, we first established USP35 knockdown (shUSP35) or knockout (sgUSP35) cells

(Supplementary Fig. 2A–F). The phosphorylation levels of the TBK1 and IRF3 were detected in B16F10, A375, and Yummer1.7 at different time points after VSV stimulation. The results showed

that the phosphorylation of both TBK1 and IRF3 was significantly enhanced in the shUSP35 group or the sgUSP35 group compared to control cells (Fig. 5B, D–F, Supplementary Fig. 4B, D, E, F).

Similar results were observed in HeLa and ID8 with knockdown of USP35 (Fig. 5A, C, Supplementary Fig. 4A, C). Restoration of Myc-USP35 in USP35-depleted A375 inhibited TBK1 and IRF3

activation upon RNA virus stimulation (Supplementary Fig. 3C). These results suggest that USP35 inhibits MAVS activity to restrain type I interferon production. To confirm these findings, we

rescued Myc-USP35-WT expression in USP35-knockdown A375 and stimulated them with RNA viruses, which were found to fail to activate TBK1 or IRF3 phosphorylation (Supplementary Fig. 3C),

further supporting the role of USP35 in inhibiting MAVS activity. These results suggest that USP35 negatively regulates MAVS activity, thereby restraining type I interferon production. THE

KNOCKDOWN OF USP35 ENHANCES THE ANTI-TUMOR IMMUNITY OF ONCOLYTIC VIRUSES IN MALIGNANT MELANOMA Oncolytic viruses (OV) are applied in the treatment of advanced or metastatic malignant

melanoma by inducing innate and adaptive immune responses to exert their anti-tumor effects [4]. Given that oncolytic virus activates the RNA signaling pathway [23], we hypothesized that the

knockdown of USP35 might enhance the anti-tumor immunity triggered by OVs. To test this, a xenograft mouse model of malignant melanoma was established with B16F10 (Fig. 6A). Significant

tumor shrinkage was observed in the shUSP35+OV group compared with the shNC+OV group (Fig. 6B–D), with no significant difference in body weight between the groups (Supplementary Fig. 5C). To

better understand how USP35 modulates the anti-tumor ability of oncolytic virotherapy, CD4+/CD8+ T cell and macrophage type were analyzed by flow cytometric assays (Supplementary Fig. 5A,

B, Supplementary Fig. 6A, B). The number of CD8+ T cells was significantly increased in the shUSP35+OV group compared to the shNC+OV group (Fig. 6E, F). CD8+ T cells were significantly

increased in the shNC+OV group compared to the shNC+PBS group (Fig. 6F), consistent with the previous report showing that oncolytic viruses reprogrammed the immunosuppressed tumor

microenvironment into CD8+ T cell-biased anti-tumor immunity [24]. No significant difference in CD4+ T cell infiltration was observed between the above two groups (Supplementary Fig. 5D, E).

Macrophages exist in two main polarization states: M1-type, which has pro-inflammatory characteristics, and M2-type, which is typically anti-inflammatory [25]. CD206 is a specific marker

for M2 macrophages [26]. Compared to the group of shNC combined with H101, the CD206 macrophages were significantly reduced in the group with shUSP35 combined with H101 (_P_ < 0.05) (Fig.

6G, H, Supplementary Fig. 6A, B). Furthermore, qRT-PCR analysis revealed higher mRNA expression levels of IFNβ, CXCL10, and CCL5 in the shUSP35+OV group compared to the shNC+OV group

(Supplementary Fig. 6C–H). These findings suggest that the knockdown of USP35 could enhance the anti-tumor immunity of oncolytic virotherapy by increasing CD8+ T infiltration, decreasing M2

macrophage polarization, and promoting the expression of key inflammatory factors such as IFNβ, CXCL10, and CCL5. In summary, we identified the deubiquitinase USP35 as a host factor

modulating MAVS activity during the infection of RNA viruses. USP35 directly binds to MAVS and relies on its deubiquitinating enzyme activity. thereby inhibiting its function. (Fig. 7).

Knockdown of USP35 enhances the anti-tumor immunity of malignant melanoma to oncolytic virotherapy. DISCUSSION Innate immunity serves as the first line of defense against pathogen invasion.

RNA and DNA recognition are mediated by RLR-MAVS and cGAS-STING signaling pathways, respectively, which initiate the production of various cytokines such as IFN-I by activating the

transcription factors IRF3 [27]. Besides its role in defending viral infection, IFN-I is also crucial for natural cancer immunosurveillance [28]. Using the luciferase reporter assay, we

found that USP35 inhibits RIG-I and MAVS-mediated IFN-β reporter gene expression. Additionally, USP35 knockdown enhanced the expression of IFN-β, CXCL10, and ISG15 triggered by RNA viruses

or exogenous RNA-3pRNA. A recent study suggests that USP35 interacts with STING to regulate STING activity and suppresses the antiviral type-I interferon response [17]. Our findings further

underscore the role of USP35 in negatively regulating the MAVS-TBK1-IRF3 signaling pathway, and the knockdown of USP35 enhances type I interferon and inflammation-related factor expression

in response to cytoplasmic RNA virus or RNA analog. MAVS is an essential adapter protein in the RLR pathway and plays a key role in the production of type I IFN [29]. Post-translational

modifications (PTMs) of MAVS are critical for for regulating itsactivity. Ubiquitination modification is a common PTM in the RLR signaling pathway. Virus infection causes K63-linked

ubiquitination of MAVS in the outer mitochondrial membrane and then induces aggregation of MAVS, which is a marker of its activation [12]. The TRIM31-mediated linked ubiquitination of K63

plays an active role in the antiviral immune pathways [30]. USP18 specifically enhances the level of ubiquitination modification of MAVS and promotes ubiquitination modification and

aggregation at the K63 position of MAVS [31]. In this study, Co-IP, GST-pull down and immunofluorescence experiments have shown that USP35 binds directly to MAVS. Deubiquitination

experiments demonstrate that MAVS is a direct substrate of USP35 and USP35 can removes the ubiquitination modification by K63 type of MAVS through its deubiquitination activity. Besides, how

USP35 modulates the activity of MAVS spatially and temporally should be fully dissected and investigated. Tumor-derived type I IFN and antigen-containing RNA can activate antigen-presenting

cells (APC), mainly including DCs and macrophages. The RNA sensors in APCs sense the RNA and promote DC maturation and M1 polarization of macrophages. These cells then trigger the

production of type I IFN and other proinflammatory factors that promote the anti-tumor immune microenvironment through the activation of T cells and NK cells, and inhibition of Treg and MDSC

cells [32, 33]. Substantial evidence from preclinical studies supports the potential RLRs-targeted therapies in cancer treatment [34]. Oncolytic viruses selectively modify the viral genome

to replicate in cancer cells and lyse cancer cells without affecting normal cells, as well as inducing an immune response in infected tumor cells [24]. Herpes simplex virus type 1 (HSV-1), a

double-stranded linear DNA virus, is another oncolytic virus used in the treatment of cancer. HSV-1 infection induces mitochondrial damage and mtDNA release, which triggers cGAS/STING/IRF3

and RIG-I-MAVS signaling [23]. Recombinant human type 5 adenovirus (Ankori, H101) is a commonly used oncolytic adenovirus, which was obtained by knocking out the E1B-55KD gene fragment and

part of the E3 region of wild-type human type 5 adenovirus by genetic engineering techniques [35]. It belongs to a DNA virus, but it can also be recognized by the RIG-I receptors.

Specifically, the AT-rich double-stranded DNA (dsDNA) is transcribed by RNA pol III into a 5′triphosphate RNA, which further activates the RIG-I-MAVS pathway to induce the production of

interferon [36]. Despite the potential of oncolytic viruses, they still face limitations including oncolytic efficacy, tumor targeting, and biosafety. Strategies to enhance combination

therapies and improve treatment sensitivity are crucial for improving the survival of melanoma patients. To further evaluate the effectiveness of the combination therapy, we investigated the

impact of USP35 knockdown on anti-tumor of oncolytic virotherapy using a mouse model of malignant melanoma. We observed that knockdown of USP35 combined with oncolytic virotherapy

significantly inhibited the growth of B16F10. Compared to the control group, the combination therapy led to a notable increase in the number of CD8+T cells, a decreased M2 type macrophages,

and elevated production of inflammatory factors including IFNβ. These findings suggest that targeting USP35 enhances anti-tumor immunity and boosts the efficacy of oncolytic virotherapy.

There is an interaction between RNA and DNA sensing pathways in the immune response. RIG-I-like receptors can detect RNA viruses, DNA viruses, and pathogenic RNA produced during certain

bacterial infections to enhance the immune response to pathogens [34]. Choi et al. showed that RIG-I may also detect DNA, suggesting that immunogenic DNA (or its transcribed RNA) may

activate RLR [37]. Furthermore, the HSV-1 virus, a DNA virus discussed earlier, induces mitochondrial damage and release of mitochondrial DNA (mtDNA) upon infection, triggering both the

cGAS/STING/IRF3 and RIG-I-MAVS signaling pathways [23]. These findings highlight that both RNA viruses, represented by VSV, and DNA viruses such as HSV-1, can activate the RIG-I-MAVS-IFNβ

pathway via distinct mechanisms, thus contributing to tumor immunotherapy. Zhang et al. suggested that USP35 was significantly positively correlated with “melanogenesis”, and “TORC1

signaling pathway activation”, while negatively correlated with “T cell activation”, and “macrophage activation” [38]. Previous authors have demonstrated that USP35 negatively regulates

STING in the DNA signaling pathway, and our current work demonstrates that USP35 also interacts with MAVS in the RNA signaling pathway. Both DNA or RNA induction pathways stimulate the

expression of type I interferons, and USP35 knockdown enhances anti-tumor immunity in response to the oncolytic virus therapy. In addition, bioinformatics analysis suggested that USP35 was

elevated after immunotherapy, which also implies the importance of targeting USP35 in immunotherapy. In the future, we plan to continue to apply RIG-I agonists or LSD1 inhibitors to activate

the RNA signaling pathway in combination with USP35 knockdown or knockout5 in animal models to further explore the function and mechanism. In summary, Our study identified USP35 as a novel

negative regulator of the MAVS-mediated type I interferon signaling pathway in malignant melanoma cells. Targeting USP35 may offer a new therapeutic strategy to enhance anti-tumor immunity

in oncolytic virotherapy. DATA AVAILABILITY The datasets analyzed for this study are in the TCGA-SKCM project (http://www.cancer.gov/tcga). The GSE database was applied to further explore

the correlation between USP35 expression and malignant melanoma before and after in vivo treatment (GSE109485) (https://www.ncbi.nlm.nih.gov/geo). We used the GEPIA (cancer-pku. cn) online

database to perform the gene expression and a survival prognosis analysis. The R code required to reproduce these findings cannot be shared at this time as the data also form part of an

ongoing study. We used different algorithms (including xCell, QUANTISEQ, MCPcounter (R package: https://github.com/ebecht/MCPcounter), EPIC, CIBERSORTABS, and CIBERSORT) to analyze the

Tumor-infiltrating Immune Cells comprehensively. REFERENCES * Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485–502. Article  PubMed 

Google Scholar  * Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36

cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article  PubMed  Google Scholar  * Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol

Ther. 2019;20:1366–79. Article  CAS  PubMed  PubMed Central  Google Scholar  * Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat

Rev Clin Oncol. 2023;20:160–77. Article  PubMed  Google Scholar  * Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, et al. RIG-I-like helicases induce immunogenic cell death

of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 2014;21:1825–37. Article  CAS  PubMed  PubMed Central  Google Scholar  * Poeck H, Besch

R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5’-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008;14:1256–63. Article  CAS  PubMed 

Google Scholar  * Heidegger S, Wintges A, Stritzke F, Bek S, Steiger K, Koenig PA, et al. RIG-I activation is critical for responsiveness to checkpoint blockade. Sci Immunol.

2019;4:eaau8943. Article  CAS  PubMed  Google Scholar  * Belgnaoui SM, Paz S, Hiscott J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS)

adapter. Curr Opin Immunol. 2011;23:564–72. Article  CAS  PubMed  Google Scholar  * Fan X, Jin T. Structures of RIG-I-like receptors and insights into Viral RNA sensing. Adv Exp Med Biol.

2019;1172:157–88. Article  CAS  PubMed  Google Scholar  * Jacobs JL, Coyne CB. Mechanisms of MAVS regulation at the mitochondrial membrane. J Mol Biol. 2013;425:5009–19. Article  CAS  PubMed

  PubMed Central  Google Scholar  * Quicke KM, Diamond MS, Suthar MS. Negative regulators of the RIG-I-like receptor signaling pathway. Eur J Immunol. 2017;47:615–28. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Liu B, Zhang M, Chu H, Zhang H, Wu H, Song G, et al. The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS

through Lys63-linked polyubiquitination. Nat Immunol. 2017;18:214–24. Article  CAS  PubMed  Google Scholar  * Xue B, Li H, Guo M, Wang J, Xu Y, Zou X, et al. TRIM21 promotes innate immune

response to RNA viral infection through Lys27-linked polyubiquitination of MAVS. J Virol. 2018;92:e00321–18. Article  CAS  PubMed  PubMed Central  Google Scholar  * Kim YJ, Lee Y, Shin H,

Hwang S, Park J, Song EJ. Ubiquitin-proteasome system as a target for anticancer treatment-an update. ArchPharmacal Res. 2023;46:573–97. CAS  Google Scholar  * Wang Y, Serricchio M, Jauregui

M, Shanbhag R, Stoltz T, Di Paolo CT, et al. Deubiquitinating enzymes regulate PARK2-mediated mitophagy. Autophagy. 2015;11:595–606. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Tang Z, Jiang W, Mao M, Zhao J, Chen J, Cheng N. Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin. Clin Transl Med. 2021;11:e390. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Zhang J, Chen Y, Chen X, Zhang W, Zhao L, Weng L, et al. Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. Cell Death

Differ. 2021;28:139–55. Article  CAS  PubMed  Google Scholar  * Chen Y, Wang L, Jin J, Luan Y, Chen C, Li Y, et al. p38 inhibition provides anti-DNA virus immunity by regulation of USP21

phosphorylation and STING activation. J Exp Med. 2017;214:991–1010. Article  CAS  PubMed  PubMed Central  Google Scholar  * Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J,

Bluyssen HA. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine growth factor Rev. 2016;29:71–81. Article  CAS  PubMed  Google Scholar 

* Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, et al. 5’-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA.

2009;106:12067–72. Article  CAS  PubMed  PubMed Central  Google Scholar  * Liuyu T, Yu K, Ye L, Zhang Z, Zhang M, Ren Y, et al. Induction of OTUD4 by viral infection promotes antiviral

responses through deubiquitinating and stabilizing MAVS. Cell Res. 2019;29:67–79. Article  CAS  PubMed  Google Scholar  * Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic

acids by the innate immune system. Immunity. 2016;44:739–54. Article  CAS  PubMed  Google Scholar  * Berry N, Suspène R, Caval V, Khalfi P, Beauclair G, Rigaud S, et al. Herpes simplex virus

type 1 infection disturbs the mitochondrial network, leading to type i interferon production through the RNA polymerase III/RIG-I pathway. mBio. 2021;12:e0255721. Article  PubMed  Google

Scholar  * Shi G, Yang Q, Zhang Y, Jiang Q, Lin Y, Yang S, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1

immunotherapy. Mol Ther. 2019;27:244–60. Article  CAS  PubMed  Google Scholar  * Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression:

the role of tumor-associated macrophages. Crit Rev Oncol/Hematol. 2008;66:1–9. Article  PubMed  Google Scholar  * Nielsen MC, Hvidbjerg Gantzel R, Clària J, Trebicka J, Møller HJ, Grønbæk

H. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells. 2020;9:1175. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wu J, Chen ZJ. Innate immune

sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32:461–88. Article  CAS  PubMed  Google Scholar  * Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master

regulator in the cancer-immunity cycle. Mol Cancer. 2019;18:152. Article  PubMed  PubMed Central  Google Scholar  * Song Y, Zhou Y, Zhou X. The role of mitophagy in innate immune responses

triggered by mitochondrial stress. Cell Commun Signal. 2020;18:186. Article  PubMed  PubMed Central  Google Scholar  * Liu X, Zhu C, Zha H, Tang J, Rong F, Chen X, et al. SIRT5 impairs

aggregation and activation of the signaling adaptor MAVS through catalyzing lysine desuccinylation. EMBO J. 2020;39:e103285. Article  CAS  PubMed  PubMed Central  Google Scholar  * Hou J,

Han L, Zhao Z, Liu H, Zhang L, Ma C, et al. USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS. Nat Commun. 2021;12:2970. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor

function. J Immunol. 2007;178:7540–9. Article  CAS  PubMed  Google Scholar  * Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is

selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003. Article  CAS  PubMed  PubMed Central  Google Scholar  * Jiang Y, Zhang H, Wang J, Chen

J, Guo Z, Liu Y, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy. J Hematol Oncol. 2023;16:8. Article  CAS  PubMed  PubMed Central  Google Scholar  * Dong J, Li W,

Dong A, Mao S, Shen L, Li S, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. Med Oncol. 2014;31:95. Article  PubMed  Google Scholar 

* Chanut R, Petrilli V. [Cytosolic DNA sensing by the cGAS-STING pathway in cancer]. Med Sci. 2019;35:527–34. Google Scholar  * Choi MK, Wang Z, Ban T, Yanai H, Lu Y, Koshiba R, et al. A

selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA. Proc Natl Acad Sci USA. 2009;106:17870–5. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Zhang Q, Liu YJ, Li JP, Zeng SH, Shen H, Han M, et al. USP35 is a potential immunosuppressive factor in skin cutaneous melanoma. J Inflamm Res. 2022;15:3065–82.

Article  PubMed  PubMed Central  Google Scholar  Download references FUNDING This study was supported by Grants from the National Natural Science Foundation of China (81972676, 32270745),

Shanghai Shenkang Hospital Development Group Medical Enterprise Integration and Innovation Cooperation Special Project (SHDC2022CRT009), the Natural Science Foundation of Shanghai

(23ZR1466500), the Shanghai Municipal Health Commission (2022YQ067), and Jiangxi Province Natural Science Foundation for Youths (20232BAB216093). AUTHOR INFORMATION Author notes * These

authors contributed equally: Heping Zhang, Jiali Zhu, Rong He, Lin Xu. AUTHORS AND AFFILIATIONS * Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine,

Tongji University, Shanghai, China Heping Zhang, Jiali Zhu, Rong He, Lin Xu, Yunfei Chen, Haihong Yu, Xuejiao Sun, Shengpeng Wan, Xiaolan Yin, Yu’e Liu, Jie Gao, Yi Lu & Qing Xu *

Institute for Hematologic Malignancies, East Hospital, Tongji University School of Medicine, Shanghai, China Heping Zhang & Zhixiong Li * Department of Oncology, Shanghai Tenth People’s

Hospital, Tongji University School of Medicine, Shanghai, China Rong He, Xiaolan Yin, Jie Gao & Qing Xu * Shanghai Pharmaceuticals Holding Co Ltd, Shanghai, China Yue Li * Department of

Hematology, East Hospital, Tongji University School of Medicine, Shanghai, China Zhixiong Li Authors * Heping Zhang View author publications You can also search for this author inPubMed 

Google Scholar * Jiali Zhu View author publications You can also search for this author inPubMed Google Scholar * Rong He View author publications You can also search for this author

inPubMed Google Scholar * Lin Xu View author publications You can also search for this author inPubMed Google Scholar * Yunfei Chen View author publications You can also search for this

author inPubMed Google Scholar * Haihong Yu View author publications You can also search for this author inPubMed Google Scholar * Xuejiao Sun View author publications You can also search

for this author inPubMed Google Scholar * Shengpeng Wan View author publications You can also search for this author inPubMed Google Scholar * Xiaolan Yin View author publications You can

also search for this author inPubMed Google Scholar * Yu’e Liu View author publications You can also search for this author inPubMed Google Scholar * Jie Gao View author publications You can

also search for this author inPubMed Google Scholar * Yue Li View author publications You can also search for this author inPubMed Google Scholar * Zhixiong Li View author publications You

can also search for this author inPubMed Google Scholar * Yi Lu View author publications You can also search for this author inPubMed Google Scholar * Qing Xu View author publications You

can also search for this author inPubMed Google Scholar CONTRIBUTIONS HPZ conceived and designed the experiments, performed the experiments, prepared figures, analyzed the data, and wrote

the article. JLZ performed the experiments and analyzed the data. RH is responsible for database analysis; LX performed the experiments, YFC conceived and designed the experiments. HHY

performed the animal model studies. XJS, SPW, and XLY performed the experiments; YeL, JG and YL analyzed the datas. ZXL provided support and revised the manuscript, YL conceived and revised

the paper, and QX conceived and designed the experiments. CORRESPONDING AUTHORS Correspondence to Zhixiong Li, Yi Lu or Qing Xu. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare

no competing interests. CELL ETHICS All cellular experiments were approved by the Ethics Committee of Shanghai Tenth People’s Hospital (approval number 2021KN108). ANIMAL ETHICS Animal

handling and experimental procedures were approved by the Institutional Animal Care and Use Committee at Shanghai Tenth People’s Hospital, Tongji University. ADDITIONAL INFORMATION

PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Edited by Dagmar Kulms SUPPLEMENTARY INFORMATION

SUPPLEMENTARY MATERIALS ORIGINAL DATAS-WB ORIGINAL DATAS-QPCR. SUPPLEMENTARY TABLE 1 RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0

International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the

source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative

Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by

statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Zhang, H., Zhu, J., He, R. _et al._ Deubiquitination enzyme USP35 negatively

regulates MAVS signaling to inhibit anti-tumor immunity. _Cell Death Dis_ 16, 138 (2025). https://doi.org/10.1038/s41419-025-07411-8 Download citation * Received: 21 June 2024 * Revised: 12

January 2025 * Accepted: 30 January 2025 * Published: 27 February 2025 * DOI: https://doi.org/10.1038/s41419-025-07411-8 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative